Angle initiates launch of cancer diagnostic product for market research

Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.

Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.

The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers the CTCs as a "liquid biopsy" for molecular analysis of the cells.

To accelerate deployment of the Parsortix system, Angle is in the process of placing machines on loan with a limited number of key users worldwide. The key users' research work will contribute to the data sets that Parsortix is developing to support regulatory submissions for marketing and Food and Drug Administration approval.

Andrew Newland, the founder and Chief Executive of the group, said: "Launch of the Parsortix system in the research market is a key milestone moving the business from the development stage into commercialisation. We are now intending to move rapidly to establish some key collaborations with leading cancer research groups."

The share price rose 15.79% to 66p by 13:50.

NR

Recommended

Delivering profits : should you buy Royal Mail shares?
Share tips

Delivering profits : should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022
Avoid easyJet shares – there are better airlines to invest in
Share tips

Avoid easyJet shares – there are better airlines to invest in

EasyJet used to be one of Europe’s most impressive airlines. But now it is facing challenges on all fronts and losing out to the competition. Rupert …
19 May 2022
Tech stock crash – dotcom bust 2.0 is upon us
Tech stocks

Tech stock crash – dotcom bust 2.0 is upon us

It’s carnage in the tech sector as the market crashes. But that spells opportunity for canny investors, says Matthew Lynn
19 May 2022
Three things you should learn from Bill Ackman's brilliant Netflix trade
Investment strategy

Three things you should learn from Bill Ackman's brilliant Netflix trade

Hedge fund guru Bill Ackman has lost $400m selling Netflix shares. John Stepek explains why this was a brilliant trade, and outlines three things that…
19 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022
Value is starting to emerge in the markets
Investment strategy

Value is starting to emerge in the markets

If you are looking for long-term value in the markets, some is beginning to emerge, says Merryn Somerset Webb. Indeed, you may soon be able to buy tra…
16 May 2022